Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections in adults and children when prescribed by a healthcare professional.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klacid is a macrolide antibiotic used to treat infections caused by susceptible bacteria. - Community‑acquired pneumonia: effective in resolving bacterial lung infection. - Acute bacterial sinusitis: reduces sinus inflammation and bacterial load. - Acute otitis media: clears middle‑ear bacterial infection. - Skin and soft tissue infections: treats cellulitis and related conditions. - Helicobacter pylori eradication: part of combination therapy to eliminate H. pylori infection.

Clarithromycin may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Altered taste: metallic or bitter sensation. - Headache: mild to moderate. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis. - Elevated liver enzymes: potential hepatotoxicity. - QT interval prolongation: risk of cardiac arrhythmia. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but serious liver injury.

When prescribing or dispensing clarithromycin, consider the following precautions. - Assess renal function: adjust use in severe impairment. - Monitor liver enzymes: watch for signs of hepatotoxicity. - Avoid in known macrolide allergy: contraindicated. - Caution with QT‑prolonging drugs: monitor cardiac rhythm. - Use with caution in pregnancy: limited safety data available. - Store at room temperature: keep in the original pack, protect from moisture.

Clarithromycin interacts with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase clarithromycin levels. - Ciclosporin: risk of nephrotoxicity, avoid co‑administration. - Simvastatin: heightened risk of rhabdomyolysis, avoid. - Pimozide: can cause serious cardiac arrhythmias, avoid.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, monitor coagulation. - Carbamazepine: may reduce clarithromycin efficacy, monitor therapeutic response.